Abstract:Diabetic kidney disease (DKD) has a strong genetic component. The marked phenotypic heterogeneity in type 2 diabetes (T2D) limits the power of cross-sectional genome-wide association studies (GWAS) on DKD. We performed a data-driven cluster analysis using the longitudinal electronic health records (EHR) of a prospective cohort to identify subgroups of patients with different patterns of progression of kidney functions. These included 29,416 Chinese patients with T2D recruited in 1995-2018 observed until 2019 (median [IQR] follow-up: 9 [5-12] years). We curated 211 variables including baseline data collected during structured assessment and follow-up EHR data. We applied generalized low rank models (GLRM) to resolve the inter-correlations among variables and reduce the high dimension of the raw dataset. We identified 6 clusters featured by distinct combinations of the 211 variables: 1) DKD-free characterized by stable estimated glomerular filtration rate (eGFR decline <1 ml/min per 1.73 m2 per year) and absence of macroalbuminuria (19.4%); 2) eGFR decline without macroalbuminuria and good glycemic and BP control (26.0%); 3) eGFR decline with albuminuria and high BP (20.1%); 4) eGFR decline with albuminuria and poor glycemic control (14.2%); 5) rapid eGFR decline, albuminuria, high BP and low glucose burden (10.5%); and 6) rapid eGFR decline, macroalbuminuria, high BP and high glucose burden (9.8%). We performed cluster-wise GWAS in 12,358 patients with available genotype data. We found diverse patterns of genetic associations for the 6 DKD clusters reaching genome-wide significance (P GWAS <5×10−8) for cluster 3 and 6. Polygenic risk scores (PRS) using top GWAS loci discriminated risk of end-stage kidney disease with AUC of 0.62 (PRS only) and 0.93 (PRS plus baseline clinical variables). Our novel cluster-GWAS using more precise phenotyping combining baseline and follow-up clinical variables had led to novel genetic discoveries. Disclosure M.Shi: None. J.C.Chan: Board Member; Asia Diabetes Foundation, Consultant; Bayer Inc., Celltrion, Boehringer Ingelheim and Eli Lilly Alliance, Sanofi, Research Support; AstraZeneca, Servier Laboratories, Viatris Inc., Hua Medicine, Merck KGaA, Applied Therapeutics Inc., Lee Powder, Pfizer Inc., Speaker's Bureau; Novartis, Stock/Shareholder; GemVCare Ltd. R.C.Ma: Advisory Panel; AstraZeneca, Merck & Co., Inc., Other Relationship; Bayer Inc., Boehringer-Ingelheim, Research Support; Tricida, Inc., Roche Diagnostics, Novo Nordisk. C.H.Tam: None. E.S.H.Lau: None. A.Yang: None. H.Wu: None. B.Fan: None. A.P.Kong: Advisory Panel; Abbott, Kyowa Kirin Co., Ltd., Speaker's Bureau; Abbott, AstraZeneca, Lilly, Bayer Inc., Boehringer Ingelheim Inc. A.Luk: Research Support; Novo Nordisk, Boehringer-Ingelheim, Bayer Inc., Speaker's Bureau; Eli Lilly and Company. E.Chow: Research Support; Medtronic, Merck KGaA, Speaker's Bureau; Novartis, Bayer Inc., Sanofi. Funding Research Grants Council of the Hong Kong Special Administrative Region (R4012-18); Theme-Based Research Scheme (T12–402/13N)

Incident heart failure and the subsequent risk of progression to end stage kidney disease in individuals with type 2 diabetes

Acute kidney injury predicts the risk of adverse cardio renal events and all cause death in southeast Asian people with type 2 diabetes

Risk Prediction and Management of Chronic Kidney Disease in People Living with Type 2 Diabetes Mellitus

A retrospective cohort study of clinical characteristics and outcomes of type 2 diabetic patients with kidney disease

Incidence of end-stage renal disease and risk factors for progression of renal dysfunction in Japanese patients with type 2 diabetes: the Fukuoka Diabetes Registry

Clinical Predictors and Long-term Impact of Acute Kidney Injury on Progression of Diabetic Kidney Disease in Chinese Patients With Type 2 Diabetes

Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study

Plasma Tryptophan-Kynurenine Pathway Metabolites and Risk for Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes

Impact of chronic kidney disease and end-stage renal disease on the mid-term adverse outcomes in diabetic patients with cardiovascular diseases

Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials

Update on diagnosis, pathophysiology, and management of diabetic kidney disease

The Analysis of Risk Factors for Diabetic Kidney Disease Progression: a Single-Centre and Cross-Sectional Experiment in Shanghai.

Progression of Heart Failure in People with Type 2 Diabetes in Germany: An Analysis Using German Health Insurance Claims Data

Risk of cardiovascular disease, death, and renal progression in diabetes according to albuminuria and estimated glomerular filtration rate

Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus

Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12)

Prognostic Implications of Type 2 Diabetes Mellitus in Heart Failure with Mildly Reduced Ejection Fraction

The Association Between Age of Onset of Type 2 Diabetes and the Long-term Risk of End-Stage Kidney Disease: A National Registry Study

Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors

1473-P: A Data-Driven Cluster Analysis of Renal Complications in Patients with Type 2 Diabetes—From Phenotypic Observation to Genetic Discovery

Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: A prospective cohort study